Value Play Or Value Trap? First Horizon National Corporation (FHN), Zimmer Biomet Holdings, Inc. (ZBH)

8 analysts out of 18 Wall Street brokerage firms rate First Horizon National Corporation (NYSE:FHN) as a Buy, while 1 see it as a Sell. The rest 9 describe it as a Hold. FHN stock traded higher to an intra-day high of $14.61. At one point in session, its potential discontinued and the price was down to lows at $14.38. Analysts have set FHN’s consensus price at $16.46, effectively giving it a 13.6% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $20 (up 38.03% from current price levels). FHN has a 12.6% ROE, lower than the 16.77% average for the industry. The average ROE for the sector is 16.23%.

It is expected that in Jun 2019 quarter FHN will have an EPS of $0.37, suggesting a 2.78% growth. For Sep 2019 is projected at $0.39. It means that there could be a 8.33% growth in the quarter. Yearly earnings are expected to rise by 4.96% to about $1.48. As for the coming year, growth will be about 6.76%, lifting earnings to $1.58. RSI after the last trading period was 55.71. FHN recorded a change of 2.62% over the past week and returned -2.56% over the last three months while the FHN stock’s monthly performance revealed a shift in price of 0.98%. The year to date (YTD) performance stands at 10.11%, and the bi-yearly performance specified an activity trend of 2.26% while the shares have moved -24.41% for the past 12 months.

First Horizon National Corporation (FHN) currently trades at $14.49, which is lower by -1.09% its previous price. It has a total of 317.84 million outstanding shares, with an ATR of around 0.33. The company’s stock volume rose to 3.42 million, better than 2.93 million that represents its 50-day average. A 5-day increase of about 2.62% in its price means FHN is now 10.11% higher on year-to-date. The shares have surrendered $43445.51 since its $19.43 52-week high price recorded on 20th of June 2018. Overall, it has seen a growth rate of -24.41 over the last 12 months. The current price per share is $2.19 above the 52 week low of $12.30 set on 26th of December 2018.

First Horizon National Corporation (NYSE:FHN)’s EPS was $0.35 as reported for the March quarter. In comparison, the same quarter a year ago had an EPS of $0.34. That means that its growth in general now stands at 3%. Therefore, a prediction of $0.34 given by the analysts brought a positive surprise of 3%. FHN March quarter revenue was $435.55 million, compared to $434.19 million recorded in same quarter last year, giving it a 0% growth rate. The company’s $1.36 million revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) shares depreciated -0.75% over the last trading period, taking overall 5-day performance up to -0.43%. ZBH’s price now at $119.79 is weaker than the 50-day average of $121.05. Getting the trading period increased to 200 days, the stock price was seen at $119 on average. The general public currently hold control of a total of 204.09 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 204.09 million. The company’s management holds a total of 0.1%, while institutional investors hold about 91.6% of the remaining shares. ZBH share price finished last trade 2.65% above its 20 day simple moving average and its upbeat gap from 200 day simple moving average is 0.64%, while closing the session with -1.17% distance from 50 day simple moving average.

Zimmer Biomet Holdings, Inc. (ZBH) shares were last observed trading -10.97% down since September 21, 2018 when the peak of $134.55 was hit. Last month’s price growth of 0.88% puts ZBH performance for the year now at 15.49%. Consequently, the shares price is trending higher by 23.51%, a 52-week worst price since Dec. 24, 2018. However, it is regaining value with 6.95% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $118.16 and $118.98. The immediate resistance area is now $120.73 Williams’s %R (14) for ZBH moved to 31.04 while the stochastic %K points at 73.2.

ZBH’s beta is 1.2; meaning investors could reap higher returns, although it also poses higher risks. The company allocated $-1.49 per share from its yearly profit to its outstanding shares. Its last reported revenue is $1.98 billion, which was -2% versus $2.02 billion in the corresponding quarter last year. The EPS for Mar 19 quarter came in at $1.87 compared to $1.91 in the year-ago quarter and had represented -2% year-over-year earnings per share growth. ZBH’s ROA is -1.2%, lower than the 10.43% industry average. Although a more robust percentage would be better, consideration is given to how well peers within the industry performed. Companies within the sector had an ROA of 10.65%.